Ongoing Projects: Kidney Disease and Cardiovascular Risk

Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney Injury (TRIBE-AKI Consortium)

Principal Investigator: Chirag Parikh

Funding Source: NIH Heart, Blood, and Lung Institute (5R01HL085757)

Project Summary: This grant will study three biomarkers for early diagnosis of acute kidney injury in 3,000 cardiac surgery patients. The biomarkers include interleukin, neutrophil gelatinase-associated lipocalin (ngal), and cystatin C.

Kidney tubular damage and dysfunction identify a novel axis of chronic kidney

Principal Investigator: Michael G. Shlipak and Joachim H. Ix

Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK098234)

Project Summary: Among 4,300 SPRINT participants with eGFR < 60ml/min/1.73m2 at baseline, we will (1) determine the association of kidney tubular dysfunction and injury with risk of cardiovascular disease events, (2) determine the association of kidney tubular dysfunction and injury with chronic kidney disease progression, and (3) determine whether randomization to the intensive vs. standard blood pressure arms slows progression of kidney tubular dysfunction and injury in patients with chronic kidney disease.

Early Detection of Chronic Kidney Disease to Reduce Cardiovascular Events

Principal Investigator: Carmen A. Peralta

Funding Source: American Heart Association- Established Investigator Award (17EIA33410161)

Summary: Chronic kidney disease (CKD), defined as a glomerular filtration rate (GFR), affects over 20 million Americans. CKD is frequently unrecognized by providers. Early detection and prevention would almost certainly be the most effective strategy to reduce the burden of CKD, as has been demonstrated by our experience with CVD in the U.S. The general hypothesis is that early detection of CKD, followed by treatment optimization can reduce CVD complications (primary prevention) and attenuate CKD progression (secondary prevention). There is an urgent need for research to test the value of early detection of CKD to reduce CVD and CKD progression. We envision a pragmatic, cluster-randomized clinical trial to evaluate the effectiveness of a CKD screening program followed by incrementally intensified treatment strategies to reduce CVD risk, delay CKD progression, and reduce costs among high risk adults with screen-detected CKD.